Nearly halfway to meeting its goal of enrolling 10,000 people for its study looking at the impact of genomic-risk information on people's lives, the Coriell Institute updated researchers and industry representatives on the initiative at a conference on consumer genetics in Boston last week.

According to Erynn Gordon, senior genetic counselor at Coriell Institute, the personalized medicine project has so far enrolled 4,000 participants, and at this rate is hoping to meet its goal of 10,000 participants by 2010.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.